Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection

World Journal of Gastroenterology

Volumn 20, Issue 22, 2014, Pages 6707-6715

  Sagnelli, Evangelista ^a,b   Sagnelli, Caterina ^a   Pisaturo, Mariantonietta ^a,b   Coppola, Nicola ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Infectious Diseases   (Italy)

Author keywords

Chronic hepatitis C virus infection; Hepatic flares; Hepatic flares in immunocompromised patients; Hepatitis A virus superinfection; Immunocompromised patients

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 28B; PEGINTERFERON; PREDNISONE; RIBAVIRIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCRISTINE; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AUTOIMMUNE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG INDUCED DISEASE; FOLLOW UP; HEPATIC FLARE; HEPATITIS; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATORY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PREVALENCE; SCORING SYSTEM; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; DISEASE COURSE; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PATHOGENICITY; RISK FACTOR; SUPERINFECTION; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; RISK FACTORS; SUPERINFECTION; TREATMENT OUTCOME;

EID: 84902151402     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i22.6707     Document Type: Article

References (105)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567 [PMID: 16122679 DOI: 10.1016/S1473-3099(05)70216-4]
2. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61 [PMID: 18039107 DOI: 10.1146/annurev.pathol.1.110304.100230]
3. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645]
4. Götz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS 2005; 19: 969-974 [PMID: 15905679]
5. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, van der Meer JT, de Vries HJ, Mulder JW, van Agtmael M, Jurriaans S, Wolthers KC, Coutinho RA. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196: 230-238 [PMID: 17570110]
6. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, Fisher M, Johnson AM, Dusheiko GM. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-991 [PMID: 17457092]
7. Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill 2010; 15: 19673 [PMID: 20929655]
8. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, Babudieri S, Toti M, Francavilla R, Ancarani F, Antonucci G, Scotto G, Di Marco V, Pastore G, Stroffolini T. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006; 43: 1154-1159 [PMID: 17029134]
9. Filippini P, Coppola N, Scolastico C, Rossi G, Onofrio M, Sagnelli E, Piccinino F. Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis 2001; 28: 725-729 [PMID: 11725228]
10. Gentile I, De Stefano A, Di Flumeri G, Buonomo AR, Carlomagno C, Morisco F, De Placido S, Borgia G. Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. In Vivo 2013; 27: 527-529 [PMID: 23812225]
11. Gentile I, Di Flumeri G, Scarica S, Frangiosa A, Foggia M, Reynaud L, Borgia G. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol 2013; 65: 83-84 [PMID: 23538314]
12. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001; 33: 321-327 [PMID: 11172332 DOI: 10.1053/ jhep.2001.22112]
13. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A, Rosen HR. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007; 196: 1474-1482 [PMID: 18008226 DOI: 10.1086/522608]
14. Deutsch M, Papadopoulos N, Hadziyannis ES, Koskinas J. Clinical characteristics, spontaneous clearance and treatment outcome of acute hepatitis C: a single tertiary center experience. Saudi J Gastroenterol 2013; 19: 81-85 [PMID: 23481134 DOI: 10.4103/1319-3767.108479]
15. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-1754 [PMID: 19587449]
16. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009; 66: 733-756 [PMID: 19011759 DOI: 10.1007/ s00018-008-8270-4]
17. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 10.1038/nature08463]
18. Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009; 10: 1819-1837 [PMID: 19891557 DOI: 10.2217/ pgs.09.121]
19. Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014; 33: 559-567 [PMID: 24081499]
20. Fortunato G, Calcagno G, Bresciamorra V, Salvatore E, Filla A, Capone S, Liguori R, Borelli S, Gentile I, Borrelli F, Borgia G, Sacchetti L. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008; 28: 141-152 [PMID: 18338947 DOI: 10.1089/jir.2007.0049]
21. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999; 73: 2938-2946 [PMID: 10074143]
22. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344 [PMID: 10764648 DOI: 10.1126/science.288.5464.339]
23. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat 2007; 14: 213-220 [PMID: 17305887 DOI: 10.1111/ j.1365-2893.2006.00795.x]
24. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 Suppl 2: 3-8 [PMID: 15346240]
25. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol 1999; 31 Suppl 1: 17-24 [PMID: 10622555]
26. Gentile I, Coppola N, Pasquale G, Liuzzi R, D'Armiento M, Di Lorenzo ME, Capoluongo N, Buonomo AR, Sagnelli E, Morisco F, Caporaso N, Borgia G. A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. Hepat Mon 2013; 13: e8352 [PMID: 23967022 DOI: 10.5812/hepatmon.8352]
27. Coppola N, Gentile I, Pasquale G, Buonomo AR, Capoluongo N, D'Armiento M, Borgia G, Sagnelli E. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2013; 13: 20-26 [PMID: 24378262]
28. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/ hep.22759]
29. Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/ SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010; 42: 81-91 [PMID: 19748329 DOI: 10.1016/j.dld.2009.08.001]
30. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553]
31. Gentile I, Viola C, Borgia F, Castaldo G, Borgia G. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009; 16: 1115-1121 [PMID: 19275615]
32. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a metaanalysis. BMC Infect Dis 2012; 12: 357 [PMID: 23245594 DOI: 10.1186/1471-2334-12-357]
33. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676]
34. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S. Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C. Clin Gastroenterol Hepatol 2013; Epub ahead of print [PMID: 24316172 DOI: 10.1016/j.cgh.2013.11.032]
35. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2014; 15: 121-130 [PMID: 24289735 DOI: 10.1517/14656566.2014.857656]
36. Gentile I, Borgia F, Coppola N, Buonomo AR, Castaldo G, Borgia G. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014; 21: 1391-1404 [PMID: 24372205]
37. Gentile I, Borgia F, Zappulo E, Buonomo AR, Spera AM, Castaldo G, Borgia G. Efficacy and Safety of Sofosbuvir in Treatment of Chronic Hepatitis C: The Dawn of the a New Era. Rev Recent Clin Trials 2013; Epub ahead of print [PMID: 23859195]
38. Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013; 20: 3733-3742 [PMID: 23848533 DOI: 10.2174/09298673113209990178]
39. Sheen IS, Liaw YF, Lin DY, Chu CM. Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. J Hepatol 1996; 24: 525-531 [PMID: 8773906]
40. Hiraga N, Suzuki F, Akuta N, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Matsuda M, Watabiki S, Satoh J, Kumada H. Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up. J Med Virol 2005; 75: 240-248 [PMID: 15602722 DOI: 10.1002/jmv.20263]
41. Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, Colombo M. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54: 402-406 [PMID: 15710990 DOI: 10.1136/gut.2004.048009]
42. Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V, Rossi G, Sagnelli C, Scolastico C, Filippini P. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005; 42: 646-651 [PMID: 15826712 DOI: 10.1016/j.jhep.2004.12.027]
43. Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 1174-1180. e11 [PMID: 23591280 DOI: 10.1016/j.cgh.2013.03.025]
44. Coppola N, Pisapia R, Marrocco C, Martini S, Vatiero LM, Messina V, Tonziello G, Sagnelli C, Filippini P, Piccinino F, Sagnelli E. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007; 40: 110-115 [PMID: 17720621 DOI: 10.1016/ j.jcv.2007.07.005]
45. Coppola N, Pisapia R, Tonziello G, Masiello A, Martini S, Pisaturo M, Messina V, Sagnelli C, Macera M, Signoriello G, Sagnelli E. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009; 46: 222-229 [PMID: 19758839 DOI: 10.1016/j.jcv.2009.08.009]
46. Sagnelli E, Tonziello G, Pisaturo M, Sagnelli C, Coppola N. Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. Antivir Ther 2012; 17: 1453-1458 [PMID: 23322703 DOI: 10.3851/IMP2471]
47. Tsuji K, Yamasaki K, Yamanishi M, Kawakami M, Shirahama S. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year followup study. J Gastroenterol Hepatol 2001; 16: 536-540 [PMID: 11350550 DOI: 10.1046/j.1440-1746.2001.02474.x]
48. Coppola N, Vatiero LM, Sagnelli E. HCV genotype 2 as a risk factor for reactivation of chronic HCV infection. Gut 2005; 54: 1207 [PMID: 16009701 DOI: 10.1136/gut.2005.070649]
49. Sagnelli E, Pisaturo M, Sagnelli C, Coppola N. Rituximabbased treatment, HCV replication, and hepatic flares. Clin Dev Immunol 2012; 2012: 945950 [PMID: 22919406 DOI: 10.1155/2012/945950]
50. Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012; 44: 49-54 [PMID: 21885355 DOI: 10.1016/j.dld.2011.07.016]
51. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116: 5119-5125 [PMID: 20823454 DOI: 10.1182/blood-2010-06-289231]
52. Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A, di Fonzo M, Begini P, Gigante E, Laverde G, Aloe-Spiriti A, Monarca B, Delle Fave G. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011; 43: 139-142 [PMID: 20554488 DOI: 10.1016/ j.dld.2010.05.010]
53. Pitini V, Sturniolo G, Arrigo C, Leonardi S, Pino S, Altavilla G. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br J Haematol 2010; 150: 116-118 [PMID: 20230413 DOI: 10.1111/j.1365-2141.2010.08154.x]
54. Thurairajah PH, Thorburn D, Hubscher S, White A, Lai WK, O'Donnell K, Mutimer D. Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1293-1300 [PMID: 17509097]
55. Caroleo B, Gallelli L, Staltari O, De Sarro G, Guadagnino V. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol. Intervirology 2008; 51: 407-409 [PMID: 19258719 DOI: 10.1159/000205266]
56. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alphainterferon. Ann Intern Med 1992; 116: 51-53 [PMID: 1727095]
57. García-Buey L, García-Monzón C, Rodriguez S, Borque MJ, García-Sánchez A, Iglesias R, DeCastro M, Mateos FG, Vicario JL, Balas A. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770-1777 [PMID: 7768382]
58. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, Verme G, Rizzetto M. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22: 1374-1378 [PMID: 7590650]
59. Bayraktar Y, Bayraktar M, Gurakar A, Hassanein TI, Van Thiel DH. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases. Hepatogastroenterology 1997; 44: 417-425 [PMID: 9164512]
60. Kogure T, Ueno Y, Fukushima K, Nagasaki F, Inoue J, Kakazu E, Matsuda Y, Kido O, Nakagome Y, Kimura O, Obara N, Wakui Y, Iwasaki T, Shimosegawa T. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol 2007; 13: 4394-4397 [PMID: 17708618]
61. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601 [PMID: 20637202 DOI: 10.1053/j.gastro.2010.07.009]
62. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012; 57: 1177-1185 [PMID: 22871500 DOI: 10.1016/ j.jhep.2012.07.031]
63. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50: 1700-1711 [PMID: 21690185 DOI: 10.1093/ rheumatology/ker190]
64. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35: 1944-1949 [PMID: 18688917]
65. Pritchard C. Etanercept and hepatitis C. J Clin Rheumatol 1999; 5: 179 [PMID: 19078381]
66. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009; 28: 787-791 [PMID: 19291350 DOI: 10.1007/s10067-009-1149-4]
67. Sagnelli E, Coppola N, Pisaturo M, Pisapia R, Onofrio M, Sagnelli C, Catuogno A, Scolastico C, Piccinino F, Filippini P. Clinical and virological improvement of hepatitis B virusrelated or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection. Clin Infect Dis 2006; 42: 1536-1543 [PMID: 16652310 DOI: 10.1086/503840]
68. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, Concia E. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-290 [PMID: 9445408]
69. Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 1771; author reply 1772-1773 [PMID: 9625635]
70. Battegay M, Naef M, Bucher HC. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 1771-172; author reply 1772-1773 [PMID: 9625636]
71. Leino T, Pebody R, Leinikki P. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 1772; author reply 1772-1773 [PMID: 9625637]
72. Martins EB. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 1772; author reply 1772-1773 [PMID: 9625638]
73. Stroffolini T, Almasio PL, Di Stefano R, Andreone P, Di Gaetano G, Fattovich G, Gaeta GB, Morisco F, Smedile A, Tripi S, Zignego AL, Ferraro D, Mele A, Craxi A. Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis. Dig Liver Dis 2002; 34: 656-659 [PMID: 12405253 DOI: 10.1016/S1590-8658(02)80209-2]
74. Cacopardo B, Nunnari G, Nigro L. Clearance of HCV RNA following acute hepatitis A superinfection. Dig Liver Dis 2009; 41: 371-374 [PMID: 18182335 DOI: 10.1016/j.dld.2007.11.015]
75. Gruener NH, Jung MC, Ulsenheimer A, Gerlach TJ, Diepolder HM, Schirren CA, Hoffmann R, Wächtler M, Backmund M, Pape GR. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J Hepatol 2002; 37: 866-869 [PMID: 12445431 DOI: 10.1016/S0168-8278(02)00303-3]
76. Guido M, Rugge M, Colombari R, Cecchetto A, Scarpa A, Cadrobbi P. Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C. Ital J Gastroenterol Hepatol 1998; 30: 414-417 [PMID: 9789140]
77. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000; 95: 2978-2980 [PMID: 11051381 DOI: 10.1016/ S0002-9270(00)01129-1]
78. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, Onofrio M, Scolastico C, Filippini P. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 1285-1291 [PMID: 12395342 DOI: 10.1053/jhep.2002.36509]
79. Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver 1999; 19: 348-353 [PMID: 10459635]
80. Biliotti E, Kondili LA, Furlan C, Ferretti G, Zacharia S, De Angelis M, Guidi S, Gusman N, Taliani G. Acute hepatitis B in patients with or without underlying chronic HCV infection. J Infect 2008; 57: 152-157 [PMID: 18538412 DOI: 10.1016/ j.jinf.2008.04.006]
81. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, Messina V, Filippini P. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009; 49: 1090-1097 [PMID: 19263473 DOI: 10.1002/hep.22794]
82. Coppola N, Marrocco C, Di Caprio D, Coviello G, Scolastico C, Filippini P, Sagnelli E. Acute hepatitis B and C virus coinfection: a virological and clinical study of 3 cases. Clin Infect Dis 2003; 36: 528-532 [PMID: 12567314 DOI: 10.1086/367650]
83. Sagnelli E, Coppola N, Marrocco C, Onofrio M, Sagnelli C, Coviello G, Scolastico C, Filippini P. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol 2006; 35: 317-320 [PMID: 16316779 DOI: 10.1016/j.jcv.2005.10.006]
84. Deterding K, Pothakamuri SV, Schlaphoff V, Hadem J, Metzler F, Bahr MJ, Manns MP, Cornberg M, Wedemeyer H. Clearance of chronic HCV infection during acute delta hepatitis. Infection 2009; 37: 159-162 [PMID: 18084714 DOI: 10.1007/s15010-007-7204-7]
85. Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Dore GJ, White PA. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2012; 55: 1058-1069 [PMID: 22031335 DOI: 10.1002/hep.24754]
86. Sagnelli E, Argentini C, Genovese D, Pisaturo M, Coppola N, Taffon S, Sagnelli C, Rapicetta M. Virological and epitope evolution of HCV infection from acute hepatitis C to subsequent episodes of HCV-related acute liver cell necrosis. Infection 2009; 37: 344-348 [PMID: 19636498 DOI: 10.1007/ s15010-008-8197-6]
87. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388-390 [PMID: 7905553]
88. Proust B, Dubois F, Bacq Y, Le Pogam S, Rogez S, Levillain R, Goudeau A. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol 2000; 38: 3125-3127 [PMID: 10921996]
89. Dove L, Phung Y, Bzowej N, Kim M, Monto A, Wright TL. Viral evolution of hepatitis C in injection drug users. J Viral Hepat 2005; 12: 574-583 [PMID: 16255758 DOI: 10.1111/ j.1365-2893.2005.00640.x]
90. Accapezzato D, Fravolini F, Casciaro MA, Paroli M. Hepatitis C flare due to superinfection by genotype 4 in an HCV genotype 1b chronic carrier. Eur J Gastroenterol Hepatol 2002; 14: 879-881 [PMID: 12172410 DOI: 10.1097/00042737-2002080 00-00012]
91. Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, Siddiqui A, Jafri W. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002; 36: 474-478 [PMID: 12143058 DOI: 10.1053/jhep.2002.34856]
92. Monga R, Garg S, Tyagi P, Kumar N. Superimposed acute hepatitis E infection in patients with chronic liver disease. Indian J Gastroenterol 2004; 23: 50-52 [PMID: 15176535]
93. Kc S, Sharma D, Basnet BK, Mishra AK. Effect of acute hepatitis E infection in patients with liver cirrhosis. JNMA J Nepal Med Assoc 2009; 48: 226-229 [PMID: 20795462]
94. Radha Krishna Y, Saraswat VA, Das K, Himanshu G, Yachha SK, Aggarwal R, Choudhuri G. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int 2009; 29: 392-398 [PMID: 19267864 DOI: 10.1111/j.1478-3231.2008.01887.x]
95. Bayram A, Eksi F, Mehli M, Sözen E. Prevalence of hepatitis E virus antibodies in patients with chronic hepatitis B and chronic hepatitis C. Intervirology 2007; 50: 281-286 [PMID: 17570930 DOI: 10.1159/000103916]
96. Sissons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus infection. J Infect 2002; 44: 78-83 [PMID: 12076065]
97. Sinzger C, Bissinger AL, Viebahn R, Oettle H, Radke C, Schmidt CA, Jahn G. Hepatocytes are permissive for human cytomegalovirus infection in human liver cell culture and In vivo. J Infect Dis 1999; 180: 976-986 [PMID: 10479121]
98. Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect 2007; 13: 953-963 [PMID: 17803749 DOI: 10.1053/jinf.2001.0949]
99. Ten Napel HH, Houthoff HJ, The TH. Cytomegalovirus hepatitis in normal and immune compromised hosts. Liver 1984; 4: 184-194 [PMID: 6087073 DOI: 10.1111/j.1469-0691.2007.01781. x]
100. Bentata-Pessayre M, Beaugrand M, Callard P, Brun-Vesinet F, Krivitsky A, Mornet P, Delzant G. [Granulomatous hepatitis in cytomegalovirus infection in healthy adults]. Ann Med Interne (Paris) 1987; 138: 353-357 [PMID: 2823662]
101. Mannstadt C, Stein G, Färber I. [Clinical aspects of acute cytomegalovirus infection in adults without immune deficiency]. Z Gesamte Inn Med 1991; 46: 107-109 [PMID: 1647571]
102. Diego Lorenzo A, de González-Asanza C, García Durán F, Piqueras B, Romero M, Salcedo M, Masud K, Cos E, Clemente G. [Cytomegalovirus infection as a cause of granulomatous hepatitis in an immunocompetent patient]. Rev Esp Enferm Dig 1996; 88: 295-297 [PMID: 9004803]
103. Kunno A, Abe M, Yamada M, Murakami K. Clinical and histological features of cytomegalovirus hepatitis in previously healthy adults. Liver 1997; 17: 129-132 [PMID: 9249726]
104. de la Serna-Higuera C, González-García M, Milicua JM, Muñoz V. [Cytomegalovirus granulomatous hepatitis in an immunocompetent patient]. Gastroenterol Hepatol 1999; 22: 230-231 [PMID: 10396104]
105. Vujacich C, Vidiella G, Barcelona L, Sturba E, Stamboulian D. [Cytomegalovirus infection with hepatic involvement in immunocompetent adults]. Medicina (B Aires) 2006; 66: 206-210 [PMID: 16871906]